A cation exchange chromatography process for purifying a peptide or GLP-1 peptide from a mixture comprising said peptide or GLP-1 peptide and related or unrelated impurities, comprising the step of: separating said peptide or GLP-1 peptide and said related or unrelated impurities of said mixture by elution in a solution comprising an organic modifier, water, optionally a salt component, and optionally a buffer, with a linear or step gradient or isocratically in salt component and/or with a linear or step pH-gradient or at a constant pH-value, wherein the pH-gradient or pH-value should be in the range where said peptide or GLP-1 peptide has a positive local or overall net charge different from the local or overall positive net charge of said related or unrelated impurities so as to remove said related or unrelated impurities
This research offers further insight into this emerging safety signal, according to the study authors who noted in their Ophthalmology paper, Our novel, stratified analysis provides a more nuanced interpretation than previous pooled reviews, isolating a potential increased risk signal to observational data in the diabetes population only, a finding not corroborated by RCTs. These results are somewhat at odds with the narrative surrounding GLP-1 use and NAION risk that began in early 2024, but the researchers say they are confident in their methodology
Lc theo: Nguyn Th Lan Hng Hu ch Hong Th Phng Cho ch Lan Hng , D, hin ti sn phm GLUMIDTAB 600 PHARBACO HP 1 L BT V 1 NG DUNG MI c gi 90.000./ hp
The scale only tells part of the story
